← Back to Home

Drugs Tailored to a Single Mutation: Two Children With SCN2A Epilepsy See Improvements of Different Magnitudes

Two antisense oligonucleotides designed to suppress only the disease-causing gene copy reduced seizures by about 26% and 90%, respectively, in two single-patient trials. The results reveal the potential of precision treatment while highlighting questions about efficacy and long-term safety that extremely small studies cannot answer.

By SURL BioNews

For families affected by rare genetic diseases, “not enough patients to conduct a large trial” often also means that no drug is available. Now, researchers have created separate personalized antisense oligonucleotides (ASOs) for two boys with severe SCN2A-related developmental and epileptic encephalopathy. After about two years of treatment, both experienced fewer seizures and varying degrees of developmental progress, providing rare clinical examples of drug development centered on a single patient.

The two parallel, open-label n-of-1 trials enrolled patients aged 9 and 14, respectively. SCN2A produces a sodium ion channel used by nerve cells; certain pathogenic variants disrupt neural signaling, causing treatment-resistant epilepsy and severe developmental impairment. Each ASO targets an intronic single-nucleotide polymorphism linked to the disease-causing SCN2A copy, thereby reducing mutant messenger RNA while preserving expression of the normal copy as much as possible, rather than indiscriminately suppressing the entire gene.

The drugs were injected into the cerebrospinal fluid under anesthesia, with dosing repeated every two to three months thereafter. Researchers tracked seizure frequency, medication use, development, and behavior, using each child’s pretreatment condition as his own control. The paper estimates that seizures decreased by 26% and 90%, respectively. The 90% reduction reached statistical significance, whereas the 26% result did not; the two cases therefore cannot be interpreted as equally conclusive evidence of efficacy.

The improvements were not reflected only in seizure records. The institutions participating in the study reported developmental progress in both children, including an adolescent who had previously been unable to walk independently and later became able to walk on his own. Such changes may be highly important in daily life, but the single-patient, uncontrolled, and unblinded design is susceptible to the disease’s natural fluctuations, changes in care, and the effects of concurrently used antiseizure medications. It is therefore not yet possible to determine how much of the improvement can be directly attributed to the ASOs.

Regarding safety, no serious adverse events judged to be related to the ASOs occurred during the study; the developer further stated that neither case involved any drug-related adverse events. However, two patients and about two years of follow-up are insufficient to rule out rare, cumulative, or delayed risks. The study, registered as NCT06314490, involves drugs regulated by the U.S. Food and Drug Administration and also shows that even when a treatment is designed for only one person, manufacturing quality, toxicology assessment, and ongoing monitoring cannot be omitted.

A clue to whether this approach can move beyond “one drug for one person” comes from another group of 19 patients: researchers identified compatible polymorphisms that could be used for a similar strategy in about 16% of them. In other words, shared genetic markers might eventually allow therapies that were originally fully customized to be extended to a small group of patients. However, the proportion eligible is limited, and human experience currently consists of only two cases. The result is more like an elegant proof-of-concept bridge—it demonstrates that a drug can be built around an individual’s genetic differences, but whether more patients can cross that bridge safely, affordably, and at scale will require longer follow-up and more cases to determine.

References

  1. Rady Children’s Institute for Genomic Medicine
  2. Nature Medicine
  3. ClinicalTrials.gov
  4. UC San Diego Today
  5. n-Lorem Foundation